CEVR analyzes the benefits, risks, and costs of strategies to improve health and health care.

About Us
Data

News & Events

Recent Publications

An evidence review of low-value care recommendations: Inconsistency and lack of economic evidence considered

Journal Of General Internal Medicine

Kim DD, Do LA, Daly AT, Wong JB, Chambers JD, Ollendorf DA, Neumann PJ. An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. J Gen Intern Med. 2021 Feb 23.

Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained

Acta Diabetologica

Olchanski N, van Klaveren D, Cohen JT, Wong JB, Ruthazer R, Kent DM. Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained. Acta Diabetologica 2021.

Eroding progress on evidence and outcomes: CMS’s new proposed pathway for medical device coverage

Health Affairs blog

Neumann PJ, Chambers JD. "Eroding progress on evidence and outcomes: CMS’s new proposed pathway for medical device coverage," Health Affairs Blog, December 2, 2020.

International reference pricing: A lazy, misguided, bi-partisan plan to lower US drug prices

Health Affairs blog

Basu A, Neumann PJ, Sullivan S. "International reference pricing: A lazy, misguided, bi-partisan plan to lower US drug prices," Health Affairs Blog, December 2, 2020.

Consideration of value-based pricing for treatments and vaccines is important, even in the COVID-19 pandemic

Health Affairs

Neumann PJ, Cohen JT, Kim DD, Ollendorf DA. Consideration of value-based pricing for treatments and vaccines is important, even in the COVID-19 pandemic. Health Affairs 2020;40(1):53–61.

Preparing the health‐care system to pay for new Alzheimer's drugs

Alzheimer's & Dementia

Lin, PJ, Cohen, JT, Neumann, PJ. Preparing the health‐care system to pay for new Alzheimer's drugs. Alzheimer's Dement. 2020; 1– 3.

Measuring “fearonomic effects” in valuing therapies: An application to COVID-19 in China

Value in Health

Ma S, Kim DD, Cohen JT, Neumann PJ. "Measuring “fearonomic effects” in valuing therapies: An application to COVID-19 in China," Value in Health (in press).

Perspective and costing in cost-effectiveness analysis, 1974–2018

PharmacoEconomics

Kim, DD, Silver, MC, Kunst, N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and costing in cost-effectiveness analysis, 1974–2018. PharmacoEconomics 38, 1135–1145 (2020).

Patient characteristics and treatment patterns among Medicare beneficiaries initiating PCSK9 inhibitor therapy

Cardiovascular Drugs and Therapy

Xue F, Berklein F, Rane PB, Habib M, Lin PJ. "Patient characteristics and treatment patterns among Medicare beneficiaries initiating PCSK9 inhibitor therapy," Cardiovascular Drugs and Therapy, June 27, 2020.

Crisis into opportunity: Can COVID-19 help set a path to improved health care efficiency?

American Journal of Managed Care

Kim DD, Ollendorf DA, Neumann PJ, Fendrick M. "Crisis into opportunity: Can COVID-19 help set a path to improved health care efficiency?,"AJMC Commentary, June 17, 2020.

The economic and public health imperatives around making potential coronavirus disease-2019 treatments available and affordable

Value in Health

Forsythe S, Cohen J, Neumann P, Bertozzi SM, Kinghorn A. “The economic and public health imperatives around making potential coronavirus disease-2019 treatments available and affordable,” Value in Health, May 21, 2020.

Analyzing the cost effectiveness of policy responses for COVID-19: The importance of capturing social consequences

Medical Decision Making Research Letter

Kim DD, Neumann PJ. "Analyzing the cost effectiveness of policy responses for COVID-19: The importance of capturing social consequences," Medical Decision Making Research Letter, May 19, 2020.

Valuing and pricing Remdesivir: Should drug makers get paid for helping us get back to work?

Health Affairs Blog

Cohen JT, Neumann PJ, Ollendorf DA. "Valuing and pricing Remdesivir: Should drug makers get paid for helping us get back to work?," Health Affairs Blog, May 20, 2020.

Coverage for Biosimilars vs reference products among US commercial health plans

Journal of the American Medical Association

Chambers JD, Lai RC, Margaretos NM, Panzer AD, Cohen JT, Neumann PJ. "Coverage for Biosimilars vs reference products among US commercial health plans," Journal of the American Medical Association Research Letter, May 19, 2020.

Growth and capacity for cost‐effectiveness analysis in Africa

Health Economics

Panzer AD, Emerson JG, D'Cruz B, Patel A, Dabak S, Isaranuwatchai W, Kim DD. "Growth and capacity for cost‐effectiveness analysis in Africa," Health Economics Letter, May 15, 2020.

The CEVR Team

Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.

Meet the CEVR Team

Our Databases

Our comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.